

For more information, contact:

Ed Field, President and COO
Aldagen
919-484-2571
efield@aldagen.com

Michelle Linn
Linnden Communications
508-362-3087
linnmich@comcast.net

FOR IMMEDIATE RELEASE**Aldagen, Inc. Appoints Lyle Hohnke, Ph.D. to Board of Directors**

- Dr. Hohnke has 35 years of health care industry experience -

Durham, NC – October 15, 2008 – Aldagen, Inc. today announced the appointment of Lyle Hohnke, Ph.D. to its Board of Directors. Dr. Hohnke has over 35 years of health care industry experience, focusing on biotechnology, pharmaceuticals and medical devices. He has been a partner of Tullis Dickerson, a healthcare focused venture capital fund, since 1994 and currently serves on the board of several private and public companies.

“Lyle’s blend of scientific research, management and venture capital experience will prove to be a tremendous asset to Aldagen in both the near and long-term,” said Tom Amick, Chairman and Chief Executive Officer of Aldagen. “We look forward to benefiting from his broad range of experience in leading and managing organizations, as well as advising emerging life science companies on financing strategies.”

Dr. Hohnke began his career at Pfizer Central Research where he headed research and development in digestive diseases and later joined the University of Connecticut Health Center as Vice President for Research. He led the university into the development field as President of the University of Connecticut Research and Development Corporation and directed a state effort to establish a venture capital fund with state and corporate funding. Before joining Tullis Dickerson, Dr. Hohnke served as a General Partner of an Iowa-based venture capital fund, where he led a leveraged buyout of a division of Bayer A.G., becoming Chairman and Chief Executive Officer of Diamond Animal Health. He has a B.A. from Western Michigan University and an M.A./Ph.D. from the University of Oregon. He was a postdoctoral fellow at U.C.L.A. School of Medicine and received an M.B.A. from the Hartford Graduate Center/R.P.I.

“I am very pleased to join the Aldagen board and be part of a company that is a leader in the exciting field of regenerative medicine,” added Dr. Hohnke.

About Aldagen, Inc.

Aldagen is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. The company has four product candidates in clinical trials. Aldagen’s most advanced product candidate, ALD-101, is currently in a pivotal Phase 3 clinical trial to evaluate its efficacy in improving umbilical cord blood transplants used to treat inherited metabolic diseases in pediatric patients. The company also is conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates: ALD 151 to improve umbilical cord blood transplants used in the treatment of leukemia, ALD-301 to treat critical limb ischemia, and ALD-201 to treat ischemic heart failure. Aldagen’s product candidates consist of specific populations of adult stem cells that the company isolates using its proprietary technology.